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Aims Incorporation of remote monitoring of pulmonary artery pressure and vital signs has been demonstrated to reduce
heart failure (HF) hospitalization and all-cause mortality in selected symptomatic HF patients. The aim of this study
is to investigate the safety and accuracy of the new CordellaTM Pulmonary Artery Pressure Sensor (Endotronix, Inc.,
Chicago, IL, USA) and the usability of the comprehensive CordellaTM Heart Failure System (CHFS).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Multicentre, open-label, irst-in-human, feasibility study to evaluate the CHFS and the safety and accuracy of the
Cordella™ Pulmonary Artery Pressure Sensor in 15 patients with New York Heart Association class III HF. All
patients were successfully implanted with the Cordella Pulmonary Artery Pressure Sensor, without sensor failure. No
device system-related complications, deined as invasive treatment, device explant or death, occurred. The primary
eficacy endpoint of a mean pulmonary artery pressure at 90 days was met in all but one patients with a cohort
difference of 2.7mmHg (Cordella Sensor 22.5± 11.8mmHg, Swan–Ganz catheter 25.2± 8.5mmHg). One patient
did not go through the 90-day right heart catheterization for safety reasons. Patient adherence to daily measurement,
transmission of vital signs and pulmonary artery pressure sensor readings were recorded 99% of the time.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion The initial experience of the CHFS incorporating comprehensive vital signs and pulmonary artery pressure monitoring
enables safe and accurate monitoring of HF status.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Incorporation of remotely monitored pulmonary artery pressure
(PAP)-guided treatment algorithm with the aim of maintaining
normal PAP range proved to be more effective in reducing heart
failure (HF) hospitalizations in selected patients with HF than
management based on symptoms and clinical signs.1,2 Additionally,
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. it has also been demonstrated that structured and protocol-driven
remote monitoring of daily weights, blood pressure, heart rate and
rhythm, oxygen saturations and a self-rated health status score
through a telemedical centre management leads to a reduction
in unplanned cardiovascular admissions and all-cause mortality.3
Together, the approved CordellaTM Heart Failure System (CHFS)
and the investigational CordellaTM Pulmonary Artery Pressure
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Sensor (Endotronix, Inc., Chicago, IL, USA) provide comprehensive
clinical information including PAP, body weight, blood pressure,
heart rate and oxygen saturations of HF patients to their physicians,
allowing HF patients to be an integral part of the team and provide
a proactive HF management platform. SIRONA sought to examine
for the irst time the safety and accuracy of the Cordella Pulmonary
Artery Pressure Sensor and the usability of the CHFS.
Methods
Study design and inclusion criteria
SIRONA (ClinicalTrials.gov Identiier: NCT03375710, CEC Ref. num-
ber: 17/061U, date of favourable ethical opinion: 8 November 2017)
was a multicentre, open-label, early feasibility study to evaluate the
CHFS and the safety and accuracy of the Cordella™ Pulmonary Artery
Pressure Sensor in 15 patients with New York Heart Association
(NYHA) class III HF. The study was undertaken in accordance with
the Declaration of Helsinki and approved by local ethics commit-
tees or institutional review boards. All participants provided written
informed consent. Briely, eligible patients were men or women over
18 years with a diagnosis of NYHA class III HF with reduced or pre-
served ejection fraction treated for a minimum of 3months and stable
for 1month prior to enrolment with at least one HF-related hospi-
talization or equivalent within the last year. An estimated glomeru-
lar iltration rate of ≥30mL/min/1.73m2 and appropriate pulmonary
artery anatomy, as demonstrated by computed tomography pulmonary
angiogram (CTPA), were also required.
Study device
The CHFS (Figure 1) is a comprehensive digital HF management
technology that measures, records, and transmits vital signs (blood
pressure, heart rate, weight, oxygen saturations) and PAP data from
the patients’ home to the clinical teams for proactive management
of patients with HF. Data are transmitted for review by the clinical
team on the web-based Patient Management Portal. Quality of life
was measured with the Kansas City Cardiomyopathy Questionnaire
(KCCQ) answered by the patients directly on a patient application,
that is part of the CHFS.
The Cordella Sensor is implanted in the right pulmonary artery
(Figure 2A), and PAP is measured daily by a wireless handheld reader
(myCordella™ Patient Reader). Patients are prompted to take daily
readings using their tablets, which is part of the system, based on
the physician-scheduled time. However, patients can take as many
ad-hoc readings as desired any time, which will also be displayed in
the system. The system takes an 18 s reading of the PAP and the mean
PAP is calculated across the full 18 s with free breathing. Briely, the
patient undocks the reader from its docking station, holds it against
their chest with one hand for 18 s while seated, and re-docks in
response to an audio cue. Data (mean and beat-to-beat) are then
transmitted for review by the clinical team on the web-based Patient
Management Portal. A change of nitinol anchors was developed during
the study to accommodate a broader range of patient and vessel
anatomy and sizes and to improve stability of the device. The iteration
lengthened and angulated the distal anchor to stabilize the device
on the inferior-posterior inlection of the pulmonary artery. Seven
patients were implanted with the initial anchor design and eight patients
with the updated anchor design. .
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. Placement of the Cordella™ Pulmonary
Artery Pressure Sensor
After a minimum of 5 days of compliant use of the CHFS, patients
underwent right heart catheterization and implantation of the
Cordella™ Sensor (Figure 2B). In SIRONA, only patients with a
favourable anatomy based upon computed tomography scan were
included due to the size requirements of the initial anchor design. A
14 Fr introducer was inserted into the right femoral vein and right
heart catheterization undertaken using a 7.5 Fr Swan–Ganz catheter
(Edwards Lifesciences). Through the distal lumen of the Swan–Ganz
catheter a 0.025′′ x 260 Amplatz extra support wire (Cook) was
positioned in the right pulmonary artery and the Swan–Ganz catheter
exchanged for a 5 Fr Straight Flush angiographic catheter (Merit). Pul-
monary angiography was performed in the antero-posterior and left
anterior oblique caudal views (40mL, 2 s, 600 psi). The 0.025′′ × 260
Amplatz extra support wire was then positioned in a right lower
lobe branch of the pulmonary artery (A8–10), and the Straight Flush
catheter exchanged for the delivery system. The Cordella Sensor,
pre-mounted on the delivery system, was advanced through the
right heart and positioned at the inferior-posterior inlection of the
right pulmonary artery. Position was conirmed by hand injection of
contrast through the side-arm of the delivery system. Withdrawal
of the release wires served to free the self-aligning nitinol anchors
and secure the Cordella Sensor in the pulmonary artery. Following
implantation, the system was calibrated to a reference luid-illed
pressure measurement using the CalEQ (calibration system).
Patients remained in hospital one night post-procedure for
observation. Following implantation, daily PAP readings were
performed while seated, holding the wireless handheld sensor
reading device (myCordella™ Patient Reader) against the right
pectoral region for 20 s and vital signs (blood pressure, heart
rate, weight, oxygen saturations) were measured using the CHFS.
Data were transmitted to the myCordella™ Hub, which guides
patients on use of the peripherals, asks the patient health-related
questions, and facilitates patient–clinician communication by
re-transmitting data to the myCordella™ Patient Management Portal
(Figure 1).
Follow-up and endpoints
Post-procedure follow-up was scheduled at 1, 3, 6, 9, 12, 18, and
24months. History and clinical examination were recorded and labora-
tory assessments undertaken at each visit. Right heart catheterization
was performed at baseline and at 3- and 12-month follow-up in the
supine position. The clinicians were blinded to PAP the irst 90 days
until the accuracy check at 90-day right heart catheterization.
The primary safety endpoint was freedom from device-related
adverse events through 30 days post-procedure and pressure sensor
failure. The primary eficacy endpoint was accuracy of the Cordella
Sensor PAP measurements, compared to luid-illed catheter 90 days
post-implant. Published data estimate the error of the luid-illed
catheter as ± 4.0mmHg. For the Cordella system to be at least as
accurate as luid-illed, the combined system error has to be less than
± 5.6mmHg (root square sum of luid-illed and Cordella error) with a
95% conidence interval for the total system of ±11mmHg. Thus, the
pre-speciied primary endpoint was luid-illed catheter ± 11mmHg,
with a difference of ± 11mmHg; in order to meet this endpoint the
Cordella Sensor has to be as accurate as a standard-of-care luid-illed
catheter which is ± 4mmHg.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 The Cordella™ Heart Failure System. (A) The Cordella™ System securely transmits daily health information (weight, blood
pressure, saturations, heart rate) as well as pulmonary artery pressure (PAP) data to clinicians from the patient’s home. (B) The Cordella™
Pulmonary Artery Pressure Sensor.
Secondary eficacy endpoints included change in PAP pre- and
post-implant, frequency of HF hospitalization or equivalent, change in
quality of life (KCCQ and EQ-5D-5L) and adherence to myCordella™
Heart Failure System measurements. An independent data safety and
monitoring board reviewed all potential procedure-related serious
adverse events and adverse events.
Statistical analysis
The Cordella™ system accuracy was compared to the accuracy of
standard-of-care commercial products that use luid-illed invasive
catheters to measure PAP, which have an accuracy of ± 4mmHg.
If ± 4mmHg is assumed for both Cordella™ and luid-illed inva-
sive catheters, then the total system accuracy must be less than
± 5.6mmHg. This total system accuracy (± 5.6mmHg) translates into
95% of all Cordella readings must be within ± 11mmHg of luid-illed
catheter.4
�system =
√
�luid−illed
2 + �PA Sensor
2
5.6 mmHg =
√
42 + 42
Cordella™ readings were compared to reference readings using the
Bland–Altman method. A Bland–Altman plot displayed the difference
between the measurements from a standard right heart catheteriza-
tion and the Cordella™ device (y-axis), vs. the average of these two
measurements (x-axis) for a measurement taken within 24 h of implant .
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. and 90 days. This variance corresponds to the documented accuracy
of typical standard-of-care luid-illed invasive catheter pressure mea-
surement systems. Statistical analyses were performed in accordance
with the pre-speciied statistical analysis plan, and SAS version 9.3 (SAS
Institute Inc., Cary, NC, USA) or higher was used to analyse the data.
Results
Between December 2017 and February 2019, 19 patients with
HF stable on therapy with HF-related hospitalization within the
preceding 12 months were enrolled in the SIRONA study. After a
minimum 5-day period adherent to daily vital sign collection using
the CHFS and a qualifying CTPA and pulmonary angiogram, 15
patients were scheduled to undergo implantation of the Cordella
Pulmonary Artery Pressure Sensor (Figure 3). All patients were in
NYHA class III; the mean age was 71.4 years (range 47.6–86.5),
mean body mass index was 29 (17–39) kg/m2, 10 (67%) were male
and 4 (53%) had an ejection fraction >40% (Table 1).
All 15 patients were successfully implanted with the Cordella
Pulmonary Artery Pressure Sensor. Four adverse events, related
to the use of the CHFS, were reported: one sensor was dislodged
from the target location of deployment into the main pulmonary
artery during withdrawal of the delivery system (not requiring any
treatment and no compromise to sensor performance); transient
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
4 W. Mullens et al.
A
B
Figure 2 The CordellaTM Pulmonary Artery Pressure Sensor. (A) Schematic of the sensor implanted in the right pulmonary artery in
anterior-posterior view: target implant zone and three-dimensional reconstruction of the Cordella Sensor deployed at the target zone. (B)
Implantation technique. Pulmonary angiography in the (A) antero-posterior (PA) and (B) left anterior oblique caudal (LAO-CAU) views. (C)
0.025”× 260 cm Amplatz extra support wire in a side branch of the right pulmonary artery over which the delivery system is advanced, (D)
positioning of the Cordella Sensor in the right pulmonary artery, (E) withdrawal of release wires allows nitinol anchors to expand securing the
sensor within the vessel, and (F) inal positioning of the Cordella Sensor in the right pulmonary artery.
complete heart block was identiied in a single patient as the sensor
passed through the right heart; post-procedure minor haemoptysis
was reported in two patients (Table 2). All events resolved without
clinical sequelae or impairment of device function. No device
system-related complication, deined as invasive treatment, device
explant or death, occurred. No sensor failure occurred within
90 days. The only serious adverse event within 90 days was one
HF hospitalization.
At 90 days post-implantation, PAP values measured by the
Cordella Sensor and right heart catheterization were well matched. .
..
..
..
..
..
..
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..
.. The primary eficacy endpoint of a mean PAP was met in all
patients with a cohort difference of 2.7mmHg (Cordella Sensor
22.5± 11.8mmHg, Swan–Ganz catheter 25.2± 8.5mmHg). Sys-
tolic and diastolic PAP values were also well matched over a clin-
ically relevant pressure range (online supplementary Table S1 and
Figure 4). The one patient who had a device dislodgement during
the implant procedure did not go through the 90-day right heart
catheterization procedure as we did not want to take the risk to
further dislodge the sensor. Over the irst 90 days following implan-
tation, patient adherence to daily measurement and transmission
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Enrolment diagram (consort diagram).
Table 1 Patient demographics
Implanted population, n 15
Demographics
Age, years, mean (range) 71.44 (47.6–86.5)
Male sex, % (n) 67 (10)
Caucasian race, % (n) 100 (15)
Height, m, mean (range) 1.673 (1.48–1.86)
Weight, kg, mean (range) 78.55 (44.8–115.1)
BMI, kg/m2, mean (range) 29 (17–39)
Ejection fraction >40%, % (n) 53 (8)
MI history, % (n) 47 (7)
NYHA class III, % (n) 100 (15)
Comorbidities, % (n)
Diabetes mellitus 27 (4)
Hypertension 67 (10)
COPD 20 (3)
Atrial lutter/ibrillation 60 (9)
CAD 47 (7)
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstruc-
tive pulmonary disease; MI, myocardial infarction; NYHA, New York Heart
Association.
of vital signs was 99% and PAP sensor readings was 99% corrobo-
rated with improvements in KCCQ score and NYHA classiication
(Figure 5).
Discussion
SIRONA was a irst-in-human multicentre clinical study com-
bining the CHFS and Cordella Sensor to provide PAP, weight,
blood pressure, heart rate and oxygen saturations to patients
and physicians through a remote monitoring system in ambulatory .
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. symptomatic HF patients. The study demonstrated that implan-
tation of the Cordella Sensor was feasible and safe with excel-
lent accuracy of the Cordella Sensor PAP measurements, com-
pared to luid-illed catheter at 3-month follow-up. Additionally, the
user-friendly patient interface with measurement of PAP through
a handheld device facilitated patient engagement and empower-
ment, resulting in high compliance during the study period. As such,
the CHFS incorporating vital signs as well as PAP monitoring is
positioned to enable comprehensive proactive HF monitoring and
management.
Heart failure hospitalization rates remain unacceptably high and
are associated with substantial patient, caregiver, and economic
costs. Randomized controlled trials of non-invasive telemedical
systems compared to routine follow-up, have mostly failed to
demonstrate reduced rates of hospitalization, which probably
relates to the limitations of the signals measured as well as the
inadequate reaction to the signals. As such, a recent clinical prac-
tice update on HF by the Heart Failure Association of the European
Society of Cardiology only recommended that home telemoni-
toring ‘may be used’ to enhance patient education and motivation
and delivery of care but must be adapted to work in synergy
with existing healthcare provision, providing the cost/beneit
needs are adequately assessed.5 In contrast, remote PAP-guided
management has demonstrated to reduce HF hospitalization and
all-cause mortality in selected symptomatic HF patients in the
CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of
Pressure to Improve Outcomes in NYHA Class III Heart Failure
Patients) trial, regardless of ejection fraction.1,6 However, the cost
and technical limitations of the current system hamper widespread
implementation of this technology.
The combination of both invasive and non-invasive monitoring
systems with an easy-to-use patient–health care provider interface
has never been tested. Here we report the feasibility, safety
and compliance of this combined comprehensive telemonitoring
system together with a PAP sensor. Importantly, data were easy
to measure by the patient and sent through a user-friendly patient
experience, enabling patient engagement and empowerment. This
also allows a bidirectional line of communication between patient
and heart care providers. As illustrated in the patient proile (online
supplementary Figure S1), the integration of clinical signs and PAP
allows better phenotyping of HF, leading to a more targeted HF
approach where other approaches only using one of both systems
might fail.
The Cordella Sensor requires no leads or batteries and is
concurrently powered and interrogated via an external antenna
in the handheld reader. It is easily implanted into a branch of the
right pulmonary artery during right heart catheterization, using a
specialized delivery system with the possibility of periprocedural
injection of dye, making selective cannulation of the desired branch
possible, under local anaesthesia. The design of the anchors allows
the sensor to be placed in an anterior branch of the right pulmonic
artery, which together with its microelectronic mechanical system
designed for narrowband radiofrequency energizing and sensing,
makes an anterior reading of the device possible, thus allowing
PAP measurements in a seated position. Electromagnetic coupling
is achieved by an external antenna, which is incorporated in
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Adverse events related to the use of the Cordella Heart Failure System
Adverse event No. events Therapy Outcome
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total adverse events 4
Dislodgement of sensor 1 None Recovered without sequelae with no
impact on pulmonary artery pressure
readings
Procedural complete heart block 1 None Recovered without sequelae
Haemoptysis 2 None (n =1)
Single dose of protamine (n = 1)
Recovered without sequelae
A
B
Figure 4 Pulmonary artery pressure measurement: (A) Bland–Altman plot of mean pulmonary artery pressure 90 days following implantation.
The Cordella Pulmonary Artery Pressure Sensor readings are compared to luid-illed catheter. (B) The Cordella Pulmonary Artery Pressure
Sensor-derived waveform.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A
B C
Figure 5 Patient adherence, quality of life and New York Heart Association (NYHA) classiication. (A) Patient adherence with daily CordellaTM
Heart Failure System (CHFS) and Cordella™ Pulmonary Artery Pressure Sensor (CPAS) readings over the irst 90 days following implantation.
(B) Kansas City Cardiomyopathy Questionnaire (KCCQ) score at baseline and 90 days following implantation. (C) NYHA classiication at
baseline and 90 days following implantation.
the handheld device, which is held against the anterior chest
wall, further improving patient compliance. Pressure applied to
the sensor causes delections of the pressure-sensitive surface,
resulting in a characteristic shift in the resonant frequency.
Based upon the promising results of SIRONA, a robust clini-
cal programme is currently underway to demonstrate the safety
and eficacy of the Cordella Pulmonary Artery Pressure Sen-
sor in SIRONA 2 (NCT03375710) as well as PROACTIVE-HF
(NCT04089059).
Conclusion
The CHFS incorporating comprehensive vital signs as well as PAP
monitoring enables safe and accurate monitoring of HF status.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article. .
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. Figure S1. Single patient-derived data following informed consent,
study enrolment and pulmonary artery pressure sensor implan-
tation. (1) Improved therapeutic adherence to guideline-directed
medical therapy reduced pulmonary artery pressure. (2) Tran-
sition from angiotensin-converting enzyme inhibitor to sacubi-
tril/valsartan reduced pulmonary artery pressure. (3) Increase in
pulmonary artery pressure and decreased weight preceded hospi-
tal admission with a respiratory infection.
Table S1. Pulmonary artery pressure during 90-day right heart
catheterization.
Funding
The study was funded by Endotronix Inc. Independent data collec-
tion, monitoring and data analysis were undertaken by independent
contract research organizations (CROs). All authors had access
to data and were responsible for the decision to submit. None
of the Authors received any personal inancial compensation of
Endotronix Inc.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
8 W. Mullens et al.
Conlict of interest: A.M.K.R. reports research support from
Abbott, Medtronic, Actelion, Novartis, SoniVie, Endotronix. All
other authors have nothing to disclose.
References
1. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson
LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D,
Jeffries B, Yadav JS; CHAMPION Trial Study Group. Wireless pulmonary artery
haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
Lancet 2011;377:658–666.
2. Constanzo M, Stevenson LW, Adamson PB, Deasi AS, Heywood JT, Bourge
RC, Bauman J, Abraham WT. Interventions linked to decreased heart failure
hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC
Heart Fail 2016;4:333–344.
3. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA,
Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H,
Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C,
Tajsic M, Dreger H, Anker SD, Stangl K. Eficacy of telemedical interventional
management in patients with heart failure (TIM-HF2): a randomised, controlled,
parallel-group, unmasked trial. Lancet 2018;392:1047–1057.
4. Abraham WT, Adamson PB, Hasan A, Bourge RC, Pamboukian SV, Aaron MF,
Raval NY. Safety and accuracy of a wireless pulmonary artery pressure monitoring
system in patients with heart failure. Am Heart J 2011;161:558–566.
5. Seferovic P, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JG,
Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS,
Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli
MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJ.
Clinical practice update on heart failure 2019: pharmacotherapy, procedures,
devices and patient management. An expert consensus meeting report of the
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail
2019;21:1169–1186.
6. Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K,
Sheikh F, Eichorn E, Lamba S, Bharmi R, Agarwal R, Kumar C, Stevenson
LW. Impact of practice-based management of pulmonary artery pressures in
2000 patients implanted with the CardioMEMS sensor. Circulation 2017;135:
1509–1517.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
